We are pleased to introduce the second of four E-Updates that will be presented to you, between now and the end of the year, in a series entitled HER1 and HER2 Targeting in Breast Cancer, Volume 2. More>>

A subset of breast cancers are characterized by amplification of the HER2 oncogene and overexpression of the HER2 oncoprotein at the tumor cell surface. This distinguishing attribute has afforded unique opportunities for the development of targeted therapies for the treatment of this disease subtype. More>>

Strides made in the treatment of metastatic breast cancer (MBC) appear to prolong survival in some settings, but the cost in terms of quality of life (QOL) remains a concern. The previous four E-Updates in this series on metastatic breast cancer have focused on the various treatment options, including chemotherapy, anti-HER2 targeted therapy, antiangiogenic therapy, and hormonal therapy. In this E-Update, we turn to the role of supportive measures in the treatment of cancer,... More>>

A significant proportion of patients with non-small cell lung cancer (NSCLC) present with locally advanced, unresectable disease. For the most part, fit patients with this diagnosis are treated with combined-modality therapy. Relatively few are rendered resectable. Over the past two decades, combination chemotherapy and radiation, preferably concurrent chemoradiation, has emerged as the standard of care. However, survival gains have been offset, to some extent, by local, normal-tissue, in-field... More>>

In this latest installment in the E-Updates series of educational programs, Dr. Hyman Muss, of the University of Vermont College of Medicine and the Vermont Cancer Center, presents eight important abstracts on optimizing the use of tamoxifen and aromatase inhibitors in early breast cancer that were presented at three recent major breast cancer meetings. More>>

The issue of cancer in the elderly is of growing concern given the aging population. It is a particular issue in lung cancer, where the median age of patients is over 60. More>>

Although significant advances have been made in the systemic therapy of non–small-cell lung cancer (NSCLC) in patients with a good performance status (PS), the subgroup of patients with a poor PS has not been studied as well. More>>

The American Cancer Society estimates that in 2007, 51,190 new cases of kidney cancer will be diagnosed in the United States, and 12,890 individuals will die of the disease. More>>

In general, metastatic breast cancer (MBC) is treated systemically using chemotherapy, hormonal therapy, and newer targeted therapies when appropriate. About 75% of breast cancers test positive for estrogen receptors (ER) and progesterone receptors (PR), and estrogen stimulation of these receptors plays an important role in the proliferation of these tumors. More>>

Lung cancer is one of the most common and deadly malignancies in the United States, with an estimated 213,380 new cases in 2007 and an estimated 160,390 deaths in 2007. Approximately 85% of these patients will be diagnosed with non-small cell lung cancer (NSCLC), and only 10%-20% will have potentially curable disease. More>>